Protein arrays are powerful tools for antibody profiling and vaccine development against infectious agents. In the previous report, we successfully applied an antibody-based protein array for immunoprofiling of Plasmodium vivax infection.
Merozoite surface protein-1 (MSP-1), a major asexual blood stage antigen, and circumsporozoite protein (CSP), a component of sporozoites that includes a Plasmodium vivax B-cell epitope, are strong candidates for use in a malaria vaccine.
Carboxy-terminus of merozoite surface protein-1 (MSP-119) is the major protein on the surface of the plasmodial merozoite that acts as one of the most important blood-stage vaccine candidates.
With the permanent integration of Pvdhfr-ts gene in the genome, the transgenic Plasmodium lines expressing PvDHFR-TS are genetically stable and will be useful for screening anti-P. vivax compounds targeting PvDHFR-TS.
The results support the idea that probabilistic techniques like profile HMMs improve similarity searches.
The performances of all four malaria RDT kits were acceptable, although Humasis Malaria P.f/Pan antigen test and CareStartTM Malaria Pf/Pv Combo test gave superior performances with ROK isolates.
Among a cohort of 1,213 cases treated for Plasmodium vivax malaria from an isolated Papua New Guinean population, seven adults with severe and sustained hemolytic anemia after clearance of the peripheral parasitemia were prospectively investigated.
Having worked with numerous species of research nonhuman primates over the past 26 years, I have a keen interest in related occupational health and safety.
Currently, there are no reliable RBC invasion assays to guide the discovery of vaccines against Plasmodium vivax, the most prevalent malaria parasite in Asia and South America.
The LDR-FMA described here allows a discriminant genotyping of resistance alleles in the pvdhfr, pvdhps, and pvmdr1 genes and can be used in large-scale surveillance studies.